July 23 (Reuters) - Palla Pharma Ltd (PAL) :
- ENTERS INTO A NEW MULTI‐YEAR SUPPLY AGREEMENT WITH A EUROPEAN CUSTOMER
- 1H 2019 REVENUE IS EXPECTED TO EXCEED MAY GUIDANCE OF $24 ‐ $26 MILLION
- PAL EXPECTS TO REPORT A MODEST, MAIDEN HALF YEAR OPERATING EBITDA PROFIT
- REITERATE EXPECTATIONS OF A MODEST OPERATING EBITDA PROFIT FOR 1H 2019
- TOTAL CONTRACT REVENUE VALUE OF NOT LESS THAN US$25 MILLION
- CONFIRM ESTIMATE FOR FY 2019 REVENUE OF OVER $60 MILLION
Source text : http://bit.ly/2JZsPJM
(([email protected];))
- Forums
- ASX - By Stock
- PAL
- News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer
News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online